ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

nerandomilast

Also written as “BI 1015550”, “Nerandomilast” and “Nerandomilast formulation 1”.

Its studies are mostly in Lung Diseases, Interstitial · Idiopathic Pulmonary Fibrosis · Myositis · Scleroderma, Systemic · Amyotrophic Lateral Sclerosis, led by 2 companies.

Drug pageNerandomilast: every studyAll 36 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Apr 4, 202235 company-led studies, 8 open or runningNext primary completion: Apr 15, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Boehringer Ingelheimits history only347 open or runningphase 3since Apr 4, 2022May 7, 2012Apr 15, 2027phase 3 · NCT06806592
Gipfel Life Sciences11 open or runningphase 3since Jan 2, 2026Jan 2, 2026Jun 30, 2027phase 3 · NCT07321860

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Gipfel Life Sciences only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Aug 6, 2023Named nerandomilastINNProposed as its International Nonproprietary Name in WHO's List 129 · before, BI 1015550
  2. Jan 2, 2026First study: phase 3 study in Amyotrophic Lateral SclerosisFirst studyNCT07321860 · 60 planned

Ahead

  1. Jun 30, 2027Primary completion: phase 3 study in Amyotrophic Lateral SclerosisNCT07321860

TargetBeta

PDE4B →read by rule
“Meanwhile, nerandomilast, a selective PDE4B inhibitor, elevates intracellular cAMP in immune and glial cells, shifting pro-inflammatory signaling toward resolution and antagonizing secondary fibrotic and inflammatory cascades.”study text, by rule · the study

Other programs on PDE4B

ProgramCompanyFurthest phaseStudies
RoflumilastruleAstraZenecaphase 461
apremilastruleAmgenphase 448
ensifentrineruleMerckphase 317
difamilastruleOtsukaphase 316
tanimilastruleChiesi Farmaceuticiphase 315

Studies

The one study Gipfel Life Sciences leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07321860Amyotrophic Lateral Sclerosis3Not yet recruitingJun 30, 202760

How it is read

Names in the registry

  • “BI 1015550”, 27 entries
  • “Nerandomilast”, 10 entries
  • “Nerandomilast formulation 1”, 1 entry
  • “Nerandomilast formulation 2”, 1 entry
  • “Nerandomilast 18 mg - adult formulation”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.